The recently reported primary results of SPOTLIGHT (NCT03504397)—a global, phase 3 study in patients with CLDN18.2-positive (≥75% of tumor cells with moderate-to-strong claudin-18 (CLDN18) membranous staining), HER2-negative disease—demonstrated that both PFS and OS were significantly prolonged in patients treated with first-line zolbetuximab plus a modified FOLFOX regimen (mFOLFOX6) compared with placebo plus mFOLFOX6 (ref. 28). This evidence concerns the gene CLDN18 and neoplasm.